Full-Time
Generative AI-powered bioinformatics analysis pipelines
No salary listed
San Francisco, CA, USA
In Person
Mithrl provides data-processing services for bioinformatics using Generative AI to speed up the creation of analysis pipelines and the generation of comprehensive reports. Its platform enables clients to obtain ready-to-run pipelines and accompanying white papers or reports through a subscription or order-based model, with pricing tailored to each project. The product works by applying Generative AI and automated workflows to ingest client data, design and run analysis pipelines, and produce structured reports or white papers, all within a transparent, client-controlled environment. Mithrl differentiates itself by focusing on rapid, customized delivery for a niche bioinformatics market, offering tailored content and insights while prioritizing data transparency and avoiding third-party data sharing. The company's goal is to help clients achieve faster, reliable data analysis and documentation through accessible, contract-based services that fit their specific needs.
Company Size
11-50
Company Stage
Seed
Total Funding
$4M
Headquarters
San Francisco, California
Founded
2023
Help us improve and share your feedback! Did you find this helpful?
People at Mithrl who can refer or advise you
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Remote Work Options
Hybrid Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Wellness Program
Mental Health Support
Conference Attendance Budget
Professional Development Budget
Stock Options
Company Equity
Phone/Internet Stipend
Home Office Stipend
An Agentic AI Scientific Decision Engine for Omics: Bridging Core Lab and End User. In service of service labs. Last month, the Mithrl team headed to Pittsburgh for ABRF 2026, the annual meeting of the Association of Biomolecular Resource Facilities. ABRF is where the scientists who run core research facilities come together: the genomics labs, proteomics centers, and shared resource teams that power discovery across academia and biopharma. What makes it special is that it sits at the intersection of cutting-edge science and real-world execution. The people in the room aren't just talking about new technologies; they're the ones actually running the experiments. Its scientific poster. Mithrl Inc. were honored to be selected for a scientific poster, An Agentic AI Scientific Decision Engine for Omics: Bridging Core Lab and End User, authored and presented by, Ada Shaw, PhD, Scientific Partnerships Lead at Mithrl. Poster background: challenges. - Data complexity ≠ clearer outcomes for investigators - Bioinformatics & biology expertise rarely coexist - AI outputs: hard to verify, reproduce, or operationalize Solution: Mithrl Scientific Decision Engine. Raw Reads to Defensible Decisions; Transparent · Accurate · Reproducible Mithrl is a Scientific Decision Engine that compresses the discovery loop for pharma R&D. Mithrl may also be applied to service lab operations, to deliver data to clients in a ready-for-insights mode, with no coding or configuration required. With Mithrl[[ʼ]]s enterprise-ready agentic AI systems, bench scientists and computational biologists can accelerate analyses and contextualize results with rigorous biological insights. Mithrl enables researchers to discover new biomarkers, identify new therapeutic targets, and understand mechanisms of action, moving from raw data to reproducible insights and defensible IP opportunities. Conversations and community continue. Download its scientific poster from the recent ABRF conference in Pittsburgh, PA. Connect with Mithrl Inc. to discuss the Mithrl Scientific Decision Engine and how your discovery or services lab could gain a competitive edge in speed and delivering depth of actionable insights.
Mithrl, a San Francisco-based AI platform provider for scientific research, raised $4M in Seed funding led by Bonfire Ventures. The funds will be used to expand their go-to-market team and enhance their platform, which aids pharmaceutical and biotech firms in accelerating drug discovery. The platform allows rapid RNA sequencing data analysis without coding, enabling scientists to validate findings.